Liquidia (LQDA) Chief Medical Officer Rajeev Sells $263K of Stock
Chief Medical Officer Saggar Rajeev sold 9,218 shares of Liquidia Corporation on October 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Saggar Rajeev, Chief Medical Officer at Liquidia Corporation ($LQDA), sold 9,218 shares at an average price of $28.48, worth about $262,528.64, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $LQDA is up 24.1% to date (from the $27.67 close on Oct 12, 2026).
LQDA
Liquidia Corporation
Key Points
- Saggar Rajeev sold 9,218 shares of Liquidia Corporation at $28.48 each, totaling $262,528.64.
- Liquidia's recent stock price is around $33.77, which is 63.9% below its 52-week high of $93.61.
- Analysts maintain a consensus 'buy' rating with a mean price target of $54.38.
Get $LQDA trade alerts by text
We text you when insiders, Congress or big funds trade $LQDA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Liquidia Corporation alert may contain errors. Disclosures
Chief Medical Officer Saggar Rajeev sold 9,218 shares of Liquidia Corporation (NasdaqCM: LQDA) on October 12, 2026, for a total of $262,528.64 at a price of $28.48 each. This planned sale is part of Rajeev's strategy to manage his investments.
Other Institutional Activity in Liquidia Corporation
Blackrock Inc. grew its holdings by 5,299,329 shares, ending with 10,788,586 shares worth about $370.6 million. Vanguard Capital Management LLC added 212,206 shares, bringing its total to 3,139,183 shares valued at approximately $107.8 million. Meanwhile, Farallon Capital Management LLC sold 290,837 shares, reducing its stake to 8,365,038 shares worth about $287.3 million.
Liquidia Corporation Stock Down 2.9%
Liquidia Corporation's stock recently traded around $33.77, which is significantly below its 50-day moving average of $61.62 and 200-day moving average of $53.93. The shares are currently 63.9% below their 52-week high of $93.61, reflecting a challenging market environment for the company.
Recent Earnings
For the trailing twelve months, Liquidia reported revenue of $450.9 million and earnings per share (EPS) of $1.39. The company has shown impressive revenue growth of 1,842.7% year over year. Its next earnings report is due on November 3, 2026.
Insider Buying and Selling at Liquidia Corporation
In addition to Rajeev's sale, other insiders also sold shares on October 12, 2026. Dana Boyle sold 5,892 shares for $167,804. Sanjeev Khindri sold 1,101 shares valued at $31,356, and Michael Kaseta, the Chief Operating Officer, sold 18,938 shares for $539,354. Jason Adair also sold 7,301 shares for $207,932. All these transactions occurred on the same day as Rajeev's sale.
Analysts Set New Price Targets
On October 1, 2026, Raymond James downgraded Liquidia's rating to 'Outperform' with a price target of $53.0, down from $106.0. BTIG also downgraded its rating to 'Neutral'. Needham maintained a 'Buy' rating with a target of $72.0, while Wells Fargo downgraded to 'Equal-Weight' with a target of $30.0. The consensus rating remains 'buy' with a mean target price of $54.38 based on eight analyst opinions.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company based in Morrisville, NC. It focuses on developing treatments for rare cardiopulmonary diseases, with its lead product, YUTREPIA, aimed at pulmonary arterial hypertension. The recent insider trading suggests active management of personal investments amid a volatile market.
Bottom Line
Investors should watch for Liquidia's next earnings report on November 3, 2026, to gauge its financial health moving forward. The recent insider sales could indicate a strategic shift, but the overall analyst sentiment remains positive with a consensus 'buy' rating.
Related Filing Alerts
Source: Saggar Rajeev's Form 4 filing on $LQDA (Oct 12, 2026). Find the original filing: LQDA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts